Zai Lab Receives FDA Orphan Drug Designation for Zocilurtatug Pelitecan in Neuroendocrine Carcinomas
MT Newswires Live
Aug 03
Zai Lab (ZLAB) received the US Food and Drug Administration's orphan drug designation for its zocilurtatug pelitecan product candidate for the treatment of neuroendocrine carcinomas, the company said Monday.
The designation comes with benefits such as eligibility for development incentives, tax credits and a potential seven-year US market-exclusivity period upon product approval, Zai Lab said.
The FDA has previously granted fast track designation for zocilurtatug pelitecan in extrapulmonary neuroendocrine carcinomas and small cell lung cancer, the company added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.